Phaseline

Companies › Protagonist Therapeutics

Protagonist Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rusfertide (PTG-300)–Phase 3Polycythemia VeraApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06033586rusfertide (PTG-300)Phase 3Polycythemia VeraOncologyApr 2027
NCT05210790rusfertide (PTG-300)Phase 3Polycythemia VeraOncologyAug 2028

From the company's SEC filings

Cash and short-term investments of $800m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

3D Medicines (Sichuan) PharmaEssentia Greenwich LifeSciences Jiangsu Healthy Life Innovation Medical Technology Buzzard Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.